Dr. Mirabelli has been a Managing Director at HealthCare Ventures, LLC (HCV) since 2000. HCV, founded in 1985, is a leading venture capital group focused on investing in and building significant companies in the biopharmaceutical industry. HCV has raised over $1.6 billion in eight funds. Dr. Mirabelli serves as Chairman of the Board of Directors of Sequoia Pharmaceuticals, Inc., and as a member of the Board of Directors of CellGate, Inc., Critical Therapeutics, Inc., DecImmune Therapeutics, Inc., Galleon Pharmaceuticals, Inc. and Synovex Corporation. Prior to joining HealthCare Ventures, Dr. Mirabelli served as Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999. LeukoSite merged with Millennium Pharmaceuticals in December 1999. Dr. Mirabelli presided over the integration of LeukoSite into Millennium as President of Pharmaceutical R&D and a member of the Company’s Board of Directors until mid-2000. Dr. Mirabelli was a founder of Isis Pharmaceuticals, Inc., where he served in a number of senior research and development positions from 1989 to 1993. He was a member of SmithKline and French Laboratories R&D Division from 1981 to 1988 where he held a number of positions including Director of the Department of Molecular Pharmacology. Dr. Mirabelli received his Ph.D. degree in molecular pharmacology from Baylor College of Medicine in Houston, Texas in 1981.